Streetbeat News

Stock Prices

LRCX

A significant amount of unusual options activity has been observed for Lam Research (NASDAQ:LRCX), with a majority of investors taking a bearish stance. The price range targeted by these investors over the last three months is between $300 and $720. Wolfe Research has downgraded its action to Outperform with a price target of $825. The next earnings are expected to be released in 16 days.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:16 pm

UNH

A significant bearish stance has been taken on UnitedHealth Group (NYSE:UNH) by a large investor or institution, as indicated by unusual options trades. The sentiment among these big-money traders is 83% bearish. The whales have been targeting a price range from $450.0 to $540.0 for UnitedHealth Group over the last 3 months. Cantor Fitzgerald and HSBC have downgraded their actions on UNH with price targets of $591 and $540 respectively.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:01 pm

SCHW

A significant bearish stance has been observed in Charles Schwab's (NYSE:SCHW) options activity, with 75% of the investors opening trades with bearish expectations. The whales have been targeting a price range from $42.5 to $55.0 for Charles Schwab over the last 3 months. JMP Securities downgraded its action to Market Outperform with a price target of $77, Barclays maintained their Equal-Weight rating with a price target of $64, and Raymond James maintained their Outperform rating with a price target of $72.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:01 pm

EFX

Equifax (NYSE:EFX) has received mixed ratings from analysts in the last quarter, with 3 somewhat bullish, 2 indifferent, and 1 somewhat bearish. The average price target is $226.0, representing an upside from the current price of $178.69. However, this is a 2.16% decrease from the previous average price target of $231.00.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:00 pm

ZBH

Analysts have provided various ratings for Zimmer Biomet Holdings (NYSE:ZBH) in the last quarter, with 1 bullish, 2 somewhat bullish, 4 indifferent, and 1 somewhat bearish. The company has an average 12-month price target of $142.75, up by 1.67% from the previous average of $140.40.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:00 pm

BRP

JP Morgan has maintained its Neutral rating for BRP Group (NASDAQ:BRP) but lowered its price target from $28.00 to $27.00. BRP Group's shares are currently trading at $23.23, and a move to $27.00 would represent a 16.23% increase.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:00 pm

INSP

Analysts have provided bullish ratings for Inspire Medical Systems (NYSE:INSP) in the last quarter, with 8 total bullish ratings and 3 somewhat bullish ratings. The average 12-month price target for INSP is $349.18, which has increased by 3.44% over the past month.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:00 pm

PEN

Citigroup has maintained its Buy rating for Penumbra (NYSE:PEN) but lowered its price target from $390.00 to $320.00. Penumbra's shares are currently trading at $241.91, and a move to $320.00 would represent a 32.28% increase.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:00 pm

CRWD

DASH

XHB

CNBC's Halftime Report discussed final trades including DoorDash, CrowdStrike, and SPDR Series Trust SPDR Homebuilders ETF.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2023 | 5:00 pm

BIOR

HC Wainwright & Co. has maintained its Buy rating for Biora Therapeutics (NASDAQ:BIOR) but lowered its price target from $65.00 to $50.00. Biora Therapeutics' shares are currently trading up 5.45% over the last 24 hours, at $2.29 per share. A move to $50.00 would account for a 2085.03% increase from the current share price.

Portfolio Pulse from Benzinga Insights

October 02, 2023 | 5:00 pm